BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 19318632)

  • 1. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.
    Pointreau Y; Garaud P; Chapet S; Sire C; Tuchais C; Tortochaux J; Faivre S; Guerrif S; Alfonsi M; Calais G
    J Natl Cancer Inst; 2009 Apr; 101(7):498-506. PubMed ID: 19318632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
    Janoray G; Pointreau Y; Garaud P; Chapet S; Alfonsi M; Sire C; Jadaud E; Calais G
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26681800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.
    Posner MR; Norris CM; Wirth LJ; Shin DM; Cullen KJ; Winquist EW; Blajman CR; Mickiewicz EA; Frenette GP; Plinar LF; Cohen RB; Steinbrenner LM; Freue JM; Gorbunova VA; Tjulandin SA; Raez LE; Adkins DR; Tishler RB; Roessner MR; Haddad RI;
    Ann Oncol; 2009 May; 20(5):921-7. PubMed ID: 19179556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Induction chemotherapy and larynx preservation: is such practice useful?].
    Sarini J; Bocciolini C; Fournier C; Penel N; Kara A; Van JT; Lefebvre JL
    Bull Cancer; 2002 Apr; 89(4):411-7. PubMed ID: 12016041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laryngeal preservation by induction chemotherapy plus radiotherapy in locally advanced head and neck cancer: the M. D. Anderson Cancer Center experience.
    Shirinian MH; Weber RS; Lippman SM; Dimery IW; Earley CL; Garden AS; Michaelson J; Morrison WH; Kramer A; Byers R
    Head Neck; 1994; 16(1):39-44. PubMed ID: 7510276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
    Vermorken JB; Remenar E; van Herpen C; Gorlia T; Mesia R; Degardin M; Stewart JS; Jelic S; Betka J; Preiss JH; van den Weyngaert D; Awada A; Cupissol D; Kienzer HR; Rey A; Desaunois I; Bernier J; Lefebvre JL;
    N Engl J Med; 2007 Oct; 357(17):1695-704. PubMed ID: 17960012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
    Posner MR; Hershock DM; Blajman CR; Mickiewicz E; Winquist E; Gorbounova V; Tjulandin S; Shin DM; Cullen K; Ervin TJ; Murphy BA; Raez LE; Cohen RB; Spaulding M; Tishler RB; Roth B; Viroglio Rdel C; Venkatesan V; Romanov I; Agarwala S; Harter KW; Dugan M; Cmelak A; Markoe AM; Read PW; Steinbrenner L; Colevas AD; Norris CM; Haddad RI;
    N Engl J Med; 2007 Oct; 357(17):1705-15. PubMed ID: 17960013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
    Ghi MG; Paccagnella A; D'Amanzo P; Mione CA; Fasan S; Paro S; Mastromauro C; Carnuccio R; Turcato G; Gatti C; Pallini A; Nascimben O; Biason R; Oniga F; Medici M; Rossi F; Fila G
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):481-7. PubMed ID: 15145166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm.
    Urba S; Wolf G; Eisbruch A; Worden F; Lee J; Bradford C; Teknos T; Chepeha D; Prince M; Hogikyan N; Taylor J
    J Clin Oncol; 2006 Feb; 24(4):593-8. PubMed ID: 16380415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does induction chemotherapy still have a role in larynx preservation strategies? The experience of Institut Catala d'Oncologia in stage III larynx carcinoma.
    Majem M; Mesia R; Mañós M; Gomez J; Galiana R; Cardenal F; Juan A; Montes A; Perez FJ; Nogues J; Llluch JR
    Laryngoscope; 2006 Sep; 116(9):1651-6. PubMed ID: 16954998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy.
    Lefebvre JL; Rolland F; Tesselaar M; Bardet E; Leemans CR; Geoffrois L; Hupperets P; Barzan L; de Raucourt D; Chevalier D; Licitra L; Lunghi F; Stupp R; Lacombe D; Bogaerts J; Horiot JC; Bernier J; Vermorken JB; ;
    J Natl Cancer Inst; 2009 Feb; 101(3):142-52. PubMed ID: 19176454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study.
    Mesía R; Garcia-Saenz JA; Lozano A; Pastor M; Grau JJ; Martínez-Trufero J; Lambeaz J; Martínez-Galán J; Mel JR; González B; Vázquez S; Mañós M; Taberna M; Cirauqui B; Del Barco E; Casado E; Rubió-Casadevall J; Rodríguez-Jaráiz A; Cruz JJ;
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):473-480. PubMed ID: 28011050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Searching for less toxic larynx preservation: a need for common definitions and metrics.
    Forastiere AA; Trotti AM
    J Natl Cancer Inst; 2009 Feb; 101(3):129-31. PubMed ID: 19176460
    [No Abstract]   [Full Text] [Related]  

  • 14. Feasibility, toxicity, and efficacy of short induction chemotherapy of docetaxel plus cisplatin or carboplatin (TP) followed by concurrent chemoradio-therapy for organ preservation in advanced cancer of the hypopharynx, larynx, and base of tongue. Early results.
    Semrau S; Waldfahrer F; Lell M; Linke R; Klautke G; Kuwert T; Uder M; Iro H; Fietkau R
    Strahlenther Onkol; 2011 Jan; 187(1):15-22. PubMed ID: 21234526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group.
    Lefebvre JL; Chevalier D; Luboinski B; Kirkpatrick A; Collette L; Sahmoud T
    J Natl Cancer Inst; 1996 Jul; 88(13):890-9. PubMed ID: 8656441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.
    Haddad RI
    J Natl Cancer Inst; 2009 Aug; 101(16):1157-8; author reply 1158. PubMed ID: 19567423
    [No Abstract]   [Full Text] [Related]  

  • 17. Concurrent chemoradiotherapy with cisplatin, 5-fluorouracil, methotrexate, and leucovorin in patients with advanced resectable squamous cell carcinoma of the larynx and hypopharynx.
    Taguchi T; Tsukuda M; Mikami Y; Matsuda H; Horiuchi C; Yoshida T; Nishimura G; Ishitoya J; Katori H
    Acta Otolaryngol; 2006 Apr; 126(4):408-13. PubMed ID: 16608794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential four-drug chemotherapy and intensity-modulated radiotherapy for larynx preservation in resectable advanced larynx and hypopharynx cancer: A pilot study.
    Su X; He C; Tang T; Chen W; Li Z; Chen Y; Yang A
    Am J Otolaryngol; 2017; 38(1):52-56. PubMed ID: 27825651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer.
    Fung K; Lyden TH; Lee J; Urba SG; Worden F; Eisbruch A; Tsien C; Bradford CR; Chepeha DB; Hogikyan ND; Prince ME; Teknos TN; Wolf GT
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1395-9. PubMed ID: 16087298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II.
    Dietz A; Wichmann G; Kuhnt T; Pfreundner L; Hagen R; Scheich M; Kölbl O; Hautmann MG; Strutz J; Schreiber F; Bockmühl U; Schilling V; Feyer P; de Wit M; Maschmeyer G; Jungehülsing M; Schroeder U; Wollenberg B; Sittel C; Münter M; Lenarz T; Klussmann JP; Guntinas-Lichius O; Rudack C; Eich HT; Foerg T; Preyer S; Westhofen M; Welkoborsky HJ; Esser D; Thurnher D; Remmert S; Sudhoff H; Görner M; Bünzel J; Budach V; Held S; Knödler M; Lordick F; Wiegand S; Vogel K; Boehm A; Flentje M; Keilholz U
    Ann Oncol; 2018 Oct; 29(10):2105-2114. PubMed ID: 30412221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.